AstraZeneca plc (4.71%), Centrica plc (5.87%) and United Utilities Group plc (3.97%) are dividend WINNERS!

The income stream from AstraZeneca plc (LON: AZN), Centrica plc (LON: CNA) and United Utilities plc (LSE: UU) will keep your portfolio ticking over nicely, says Harvey Jones.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

What dividend-generating stocks can sometimes lack in growth prospects, they will hopefully more than make up for with a juicy income stream. So what do these three FTSE 100 stalwarts offer?

Patience may be rewarded

Pharmaceutical play AstraZeneca (LSE: AZN) has a strong dividend track record, and right now offers an annual 4.71% cash injection for your portfolio. Its growth history is decent as well, rising 27% over the past five years, five times the average FTSE 100 return of just over 5%. This is pretty impressive given that a number of AstraZeneca’s top-selling drugs have come off patent in recent years, hitting revenues in the short term. This means that investors must be patient to see whether chief executive Pascal Soriot’s long-term strategy for replenishing the company’s drugs pipeline gets profits gushing again. 

The aim is for new blockbuster treatments to deliver revenues of $45bn by 2023, up from $26bn last year. Right now, growth is slow, with Q1 revenue increasing by 5% to $6.1bn, although that fell to just 1% at constant exchange rates. AstraZeneca also has to bear the expense of its enlarged R&D operations, with costs rising 15% in the quarter. Total revenue and core EPS growth look set to decline as it loses Crestor exclusivity in the US. Growth may be patchy over the next couple of years, but with cover of 1.5 the dividends should still flow while we wait to see whether Soriot’s strategy is likely to prove a winner.

Hammered by public anger

The sad truth is that the only reason to have held British Gas owner Centrica (LSE: CNA) for the last five years has been the dividend. The share price is down 35% in what has been a troubled time for the company, which has been hammered by public anger over utility bills, falling wholesale energy prices, squeezed profits and the unpleasant surprise earlier this month of a £750m institutional share placing of 350m new shares.

Centrica’s response to its troubles has been to slash costs and capex, which is hardly an original strategy in the current climate, but has proved effective elsewhere. Following the commodity stock playbook, it also took a knife to its dividend, which was cut by 30%, although it is still forecast to yield 6.1% by December. Management is aiming for progression from here which will tempt investors, even those who aren’t fully convinced by their ability to turn this ailing crate around.

The best of both worlds

By comparison, United Utilities (LSE: UU) has offered the best of both worlds, with a healthy dividend and index-thrashing growth. Its share price is up 54% over the last five years, which partly explains its lower but still respectable yield of 3.97%.

The recently reported 0.6% rise in full-year revenue to £1.73bn was solid, although new regulated price controls contributed to a 9% drop in underlying operating profits to £604m. The final dividend was raised 2% to 25.6p, making a total of 38.45p for the year. Investors can hope for further progression as well, with management planning to raise dividends by at least RPI through to 2020.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Harvey Jones has no position in any shares mentioned. The Motley Fool UK has recommended AstraZeneca and Centrica. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Black father and two young daughters dancing at home
Investing Articles

1 FTSE 250 stock I own, and 1 I’d love to buy

Our writer explains why she’s eyeing up this FTSE 250 growth phenomenon, and may buy more shares in this property…

Read more »

View of Tower Bridge in Autumn
Investing Articles

The FTSE 100 is closing in on 8,000 points! Here’s what I’m buying before it’s too late!

As the FTSE 100 keeps gaining momentum, this Fool is on the lookout for bargains. Here's one stock he'd willingly…

Read more »

Investing Articles

3 ideas to help investors aim for a million-pound Stocks & Shares ISA

The UK has a growing number of Stocks and Shares ISA millionaires, and this plan may be one of the…

Read more »

Illustration of flames over a black background
Investing Articles

2 red-hot UK growth stocks to consider buying in April

These two growth stocks are performing well, but can they continue to deliver for investors through 2024 and beyond?

Read more »

Charticle

Is JD Sports Fashion one of the FTSE 100’s best value stocks? Here’s what the charts say!

The JD Sports Fashion share price remains a wild ride during the first quarter. Could it be one of the…

Read more »

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »